Skip to main content
. Author manuscript; available in PMC: 2013 Jun 21.
Published in final edited form as: Cell Mol Neurobiol. 2008 Jun 27;29(1):17–25. doi: 10.1007/s10571-008-9290-1

Fig. 2.

Fig. 2

Efficacy of CHM compared with α2-adrenergic agonists (A), and opioid agonists (B) in relieving anxiety. Summary estimates of the weighted mean differences (WMDs) and their 95% CIs are given at three time points. “Beginning” and “End” in (A) and “Beginning,” “middle,” and “End” in (B) were analyzed in fixed-effects models. The other time points were analyzed in random-effects models. NR indicates the fail-safe number, i.e. the number of unpublished negative studies that would be required to overturn each significant finding at an alpha level of 0.05